These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 26406771)

  • 1. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
    Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
    Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
    Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic-pharmacodynamic analysis of tear fluid following oral administration.
    Tamura N; Okano A; Kuroda T; Niwa H; Kusano K; Matsuda Y; Fukuda K; Mita H; Nagata S
    Vet Ophthalmol; 2020 Jul; 23(4):640-647. PubMed ID: 32383526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
    Andes D; Marchillo K; Stamstad T; Conklin R
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
    Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
    Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
    Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
    Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
    Wang T; Zhang T; Meng T; Li Y; Chen L; Yang Q; Dong H; Lei J; Chen L; Dong Y
    J Transl Med; 2018 Jun; 16(1):157. PubMed ID: 29880050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.
    Huurneman LJ; Neely M; Veringa A; Docobo Pérez F; Ramos-Martin V; Tissing WJ; Alffenaar JW; Hope W
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2336-42. PubMed ID: 26833158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients.
    Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M
    J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.